| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Guest Access | Sign In via User Name/Password
|
|
|
|||||||
Guest Access | Sign In via User Name/Password |
|||||||||
Correspondence to: Harry R. Büller, MD, Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands
This chapter about antithrombotic therapy for venous thromboembolic disease is part of the seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy: Evidence Based Guidelines. Grade 1 recommendations are strong and indicate that the benefits do, or do not, outweigh risks, burden, and costs. Grade 2 suggests that individual patients’ values may lead to different choices (for a full understanding of the grading see Guyatt et al, CHEST 2004; 126:179S–187S). Among the key recommendations in this chapter are the following: for patients with objectively confirmed deep vein thrombosis (DVT), we recommend short-term treatment with subcutaneous (SC) low molecular weight heparin (LMWH) or, alternatively, IV unfractionated heparin (UFH) [both Grade 1A]. For patients with a high clinical suspicion of DVT, we recommend treatment with anticoagulants while awaiting the outcome of diagnostic tests (Grade 1C+). In acute DVT, we recommend initial treatment with LMWH or UFH for at least 5 days (Grade 1C), initiation of vitamin K antagonist (VKA) together with LMWH or UFH on the first treatment day, and discontinuation of heparin when the international normalized ratio (INR) is stable and > 2.0 (Grade 1A). For the duration and intensity of treatment for acute DVT of the leg, the recommendations include the following: for patients with a first episode of DVT secondary to a transient (reversible) risk factor, we recommend long-term treatment with a VKA for 3 months over treatment for shorter periods (Grade 1A). For patients with a first episode of idiopathic DVT, we recommend treatment with a VKA for at least 6 to 12 months (Grade 1A). We recommend that the dose of VKA be adjusted to maintain a target INR of 2.5 (INR range, 2.0 to 3.0) for all treatment durations (Grade 1A). We recommend against high-intensity VKA therapy (INR range, 3.1 to 4.0) [Grade 1A] and against low-intensity therapy (INR range, 1.5 to 1.9) compared to INR range of 2.0 to 3.0 (Grade 1A). For the prevention of the postthrombotic syndrome, we recommend the use of an elastic compression stocking (Grade 1A). For patients with objectively confirmed nonmassive PE, we recommend acute treatment with SC LMWH or, alternatively, IV UFH (both Grade 1A). For most patients with pulmonary embolism (PE), we recommend clinicians not use systemic thrombolytic therapy (Grade 1A). For the duration and intensity of treatment for PE, the recommendations are similar to those for DVT.
Key Words: cancer • chronic thromboembolic pulmonary hypertension • deep vein thrombosis • heparin-induced thrombocytopenia • low molecular weight heparin • pulmonary embolism • thrombectomy • thrombolytic therapy • thrombophilia • thrombophlebitis • unfractionated heparin • vena cava filter • venous thromboembolism • vitamin K antagonist
This article has been cited by other articles:
|
|
 |
|
  F. J. Munoz, P. Mismetti, R. Poggio, R. Valle, M. Barron, M. Guil, M. Monreal, and for the RIETE Investigators Clinical Outcome of Patients With Upper-Extremity Deep Vein Thrombosis: Results From the RIETE Registry,{dagger} Chest, January 1, 2008; 133(1): 143 - 148. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. A. Morris, S. Castrejon, G. Devendra, and A. C. Gamst No Difference in Risk for Thrombocytopenia During Treatment of Pulmonary Embolism and Deep Venous Thrombosis With Either Low-Molecular-Weight Heparin or Unfractionated Heparin: A Metaanalysis Chest, October 1, 2007; 132(4): 1131 - 1139. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Kucher Catheter Embolectomy for Acute Pulmonary Embolism Chest, August 1, 2007; 132(2): 657 - 663. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Hoppe, J. A. Kaufman, R. E. Barton, B. D. Petersen, P. C. Lakin, T. G. DeLoughery, Z. Irani, K. Yavuz, and F. S. Keller Safety of Inferior Vena Cava Filter Retrieval in Anticoagulated Patients Chest, July 1, 2007; 132(1): 31 - 36. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. A. Binkert, M. C. Morash, and J. D. Gates Venographic Findings at Retrieval of Inferior Vena Cava Filters Am. J. Roentgenol., April 1, 2007; 188(4): 1039 - 1043. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Sellier, J. Labarere, J.-L. Bosson, M. Auvray, M.-T. Barrellier, C. Le Hello, J. Belmin, P. Le Roux, M.-A. Sevestre, and for the Association pour la Promotion de l'Angiolo Effectiveness of a guideline for venous thromboembolism prophylaxis in elderly post-acute care patients: a multicenter study with systematic ultrasonographic examination. Arch Intern Med, October 23, 2006; 166(19): 2065 - 2071. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Tremey, B. Szekely, S. Schlumberger, D. Francois, N. Liu, K. Sievert, and M. Fischler Anticoagulation monitoring during vascular surgery: accuracy of the Hemochron(R) low range activated clotting time (ACT-LR) Br. J. Anaesth., October 1, 2006; 97(4): 453 - 459. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Shapiro Critical Care of the Obstetric Patient. J Intensive Care Med, September 1, 2006; 21(5): 278 - 286. [Abstract] [PDF]
|
|
|
|
|
|
R. L. Levine, D. McCollum, and M. J. Hursting How frequently is venous thromboembolism in heparin-treated patients associated with heparin-induced thrombocytopenia? Chest, September 1, 2006; 130(3): 681 - 687. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Rubin, H. Xie, K. Kim, W. F. Weitzel, S. Y. Emelianov, S. R. Aglyamov, T. W. Wakefield, A. G. Urquhart, and M. O'Donnell Sonographic elasticity imaging of acute and chronic deep venous thrombosis in humans. J. Ultrasound Med., September 1, 2006; 25(9): 1179 - 1186. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. A Nutescu, A. K Wittkowsky, P. P Dobesh, D. W Hawkins, and W. E Dager Choosing the Appropriate Antithrombotic Agent for the Prevention and Treatment of VTE: A Case-Based Approach Ann. Pharmacother., September 1, 2006; 40(9): 1558 - 1570. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Kearon, J. S. Ginsberg, J. A. Julian, J. Douketis, S. Solymoss, P. Ockelford, S. Jackson, A. G. Turpie, B. MacKinnon, J. Hirsh, et al. Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism. JAMA, August 23, 2006; 296(8): 935 - 942. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Miller, I. Campbell, T. Fennerty, G. E. Raskob, and H. R. Buller Duration of warfarin in pulmonary embolism. Chest, July 1, 2006; 130(1): 299 - 300. [Full Text] [PDF]
|
|
|
|
 |
|
 P. de Moerloose, C. M. Samama, and S. Motte Management of venous thromboembolism: [Traitement de la maladie thromboembolique veineuse]. Can J Anesth, June 1, 2006; 53(6_suppl): S80 - S88. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. K. Ho, G. J. Hankey, D. J. Quinlan, and J. W. Eikelboom Risk of recurrent venous thromboembolism in patients with common thrombophilia: a systematic review. Arch Intern Med, April 10, 2006; 166(7): 729 - 736. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. M Witt and S. Siragusa Review: long term anticoagulation reduces recurrent venous thromboembolism Evid. Based Med., April 1, 2006; 11(2): 45 - 45. [Full Text] [PDF]
|
|
|
|
|
|
M. Levi Male sex, first idiopathic deep venous thrombosis, and oral contraception were risk factors for recurrent venous thrombotic events Evid. Based Med., April 1, 2006; 11(2): 59 - 59. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Markle-Reid Review: once daily LMWH is as effective as twice daily LMWH for initial treatment of venous thromboembolism Evid. Based Nurs., April 1, 2006; 9(2): 51 - 51. [Full Text] [PDF]
|
|
|
|
 |
|
 R. L. Sacco, R. Adams, G. Albers, M. J. Alberts, O. Benavente, K. Furie, L. B. Goldstein, P. Gorelick, J. Halperin, R. Harbaugh, et al. Guidelines for Prevention of Stroke in Patients With Ischemic Stroke or Transient Ischemic Attack: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association Council on Stroke: Co-Sponsored by the Council on Cardiovascular Radiology and Intervention: The American Academy of Neurology affirms the value of this guideline. Circulation, March 14, 2006; 113(10): e409 - e449. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J. Comerota Retrievable IVC Filters: A Decision Matrix for Appropriate Utilization Perspectives in Vascular Surgery and Endovascular Therapy, March 1, 2006; 18(1): 11 - 17. [Abstract] [PDF]
|
|
|
|
|
|
W. Lim, M. A. Crowther, and J. W. Eikelboom Management of Antiphospholipid Antibody Syndrome: A Systematic Review JAMA, March 1, 2006; 295(9): 1050 - 1057. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. L. Sacco, R. Adams, G. Albers, M. J. Alberts, O. Benavente, K. Furie, L. B. Goldstein, P. Gorelick, J. Halperin, R. Harbaugh, et al. Guidelines for Prevention of Stroke in Patients With Ischemic Stroke or Transient Ischemic Attack: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association Council on Stroke: Co-Sponsored by the Council on Cardiovascular Radiology and Intervention: The American Academy of Neurology affirms the value of this guideline. Stroke, February 1, 2006; 37(2): 577 - 617. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-L. Bosson and J. Labarere Determining indications for care common to competing guidelines by using classification tree analysis: application to the prevention of venous thromboembolism in medical inpatients. Med Decis Making, January 1, 2006; 26(1): 63 - 75. [Abstract] [PDF]
|
|
|
|
 |
|
 D. Balachandran, R. Adachi, and E. M. Marom Invited Commentary RadioGraphics, January 1, 2006; 26(1): 39 - 40. [Full Text] [PDF]
|
|
|
|
 |
|
 P. Prandoni How I treat venous thromboembolism in patients with cancer Blood, December 15, 2005; 106(13): 4027 - 4033. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Goodin Selecting an anticoagulant for recurrent venous thromboembolism in cancer Am. J. Health Syst. Pharm., November 15, 2005; 62(22_Supplement_5): S10 - S13. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Capstick and M. T. Henry Efficacy of thrombolytic agents in the treatment of pulmonary embolism Eur. Respir. J., November 1, 2005; 26(5): 864 - 874. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Thabut and D. Logeart Thrombolysis for Pulmonary Embolism in Patients With Right Ventricular Dysfunction: Con Arch Intern Med, October 24, 2005; 165(19): 2200 - 2203. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Kostrubiec, P. Pruszczyk, A. Bochowicz, R. Pacho, M. Szulc, A. Kaczynska, G. Styczynski, A. Kuch-Wocial, P. Abramczyk, Z. Bartoszewicz, et al. Biomarker-based risk assessment model in acute pulmonary embolism Eur. Heart J., October 2, 2005; 26(20): 2166 - 2172. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Mismetti, S. Quenet, M. Levine, G. Merli, H. Decousus, E. Derobert, and S. Laporte Enoxaparin in the Treatment of Deep Vein Thrombosis With or Without Pulmonary Embolism: An Individual Patient Data Meta-analysis Chest, October 1, 2005; 128(4): 2203 - 2210. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Di Nisio, S. Middeldorp, and H. R. Buller Direct Thrombin Inhibitors N. Engl. J. Med., September 8, 2005; 353(10): 1028 - 1040. [Full Text] [PDF]
|
|
|
|
|
|
P. Girard, O. Sanchez, C. Leroyer, D. Musset, G. Meyer, J.-B. Stern, F. Parent, and for the Evaluation du Scanner Spirale dans l'Embol Deep Venous Thrombosis in Patients With Acute Pulmonary Embolism: Prevalence, Risk Factors, and Clinical Significance Chest, September 1, 2005; 128(3): 1593 - 1600. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Aujesky, K. J. Smith, J. Cornuz, and M. S. Roberts Cost-Effectiveness of Low-Molecular-Weight Heparin for Treatment of Pulmonary Embolism Chest, September 1, 2005; 128(3): 1601 - 1610. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. F. Millward Function of the Gunther Tulip Vena Caval Filter Chest, September 1, 2005; 128(3): 1888 - 1889. [Full Text] [PDF]
|
|
|
|
|
|
D. Ost, J. Tepper, H. Mihara, O. Lander, R. Heinzer, and A. Fein Duration of Anticoagulation Following Venous Thromboembolism: A Meta-analysis JAMA, August 10, 2005; 294(6): 706 - 715. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Ansell Vena Cava Filters: Do We Know All That We Need to Know? Circulation, July 19, 2005; 112(3): 298 - 299. [Full Text] [PDF]
|
|
|
|
|
|
The PREPIC Study Group Eight-Year Follow-Up of Patients With Permanent Vena Cava Filters in the Prevention of Pulmonary Embolism: The PREPIC (Prevention du Risque d'Embolie Pulmonaire par Interruption Cave) Randomized Study Circulation, July 19, 2005; 112(3): 416 - 422. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Kucher and S. Z. Goldhaber Management of Massive Pulmonary Embolism Circulation, July 12, 2005; 112(2): e28 - e32. [Full Text] [PDF]
|
|
|
|
|
|
W. E Dager, J. H King, J. M Branch, S. L Chow, R. E Ferrer, S. Pak, P. Y Togioka, and R. H White Tinzaparin in Outpatients with Pulmonary Embolism or Deep Vein Thrombosis Ann. Pharmacother., July 1, 2005; 39(7): 1182 - 1187. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Falanga and L. Zacharski Deep vein thrombosis in cancer: the scale of the problem and approaches to management Ann. Onc., May 1, 2005; 16(5): 696 - 701. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Elliott and S. Stevens Review: thrombolytic treatment does not reduce the risk of recurrent pulmonary embolism and death more than heparin Evid. Based Med., April 1, 2005; 10(2): 41 - 41. [Full Text] [PDF]
|
|
|
|
 |
|
 T. L. Ortel Thrombosis and the Antiphospholipid Syndrome Hematology, January 1, 2005; 2005(1): 462 - 468. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
